Clinical trials: System Lupus Erythematosus
Systemic Lupus Erythematosus
Fatigue, Depression, and Cortical Excitability in Systemic Lupus
Systemic lupus erythematosus is a chronic inflammatory autoimmune disease with an unknown cause and many challenges. Whilst corticosteroids and effective immunosuppressive therapy have transformed the management of patients with…
- Trial name
- NCT03165682
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assiut University
Systemic Lupus Erythematosus, Arthritic Psoriasis
The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients
The purpose of this study is to investigate the effect of BMS-986165 in combination with an oral contraceptive in healthy female patients.
- Conditions
- Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
- Trial name
- NCT03262727
- Testing
- BMS-986165, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus
Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus
The primary purpose of this study is to evaluate the potential effectiveness of 24 weeks of MMF within previously discovered immunologically defined subsets of SLE patients.
- Trial name
- DIVERT (NCT05306873)
- Testing
- Mycophenolate Mofetil, Voclosporin
- Where
- 10 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Nephritis, Lupus Nephritis - WHO Class III
KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
- Conditions
- Lupus Nephritis, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV
- Trial name
- NCT06342960
- Testing
- KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
- Where
- 6 sites in Germany
- Volunteers
- 2 people
- Sponsor
- Kyverna Therapeutics
Lupus Erythematosus, Systemic, Sjogren's Syndrome
Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome
The purpose of the study is to examine whether dehydroepiandrosterone (DHEA) administration improves fatigue and general well-being in patients with systemic lupus erythematosus or primary Sjögren's syndrome
- Trial name
- NCT00391924
- Testing
- Dehydroepiandrosterone
- Where
- 2 sites in Netherlands
- Volunteers
- 120 people
- Sponsor
- UMC Utrecht
Kidney Diseases, Lupus Nephritis
Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis
The purpose of this study is to compare the efficacy and safety of tacrolimus vs intravenous cyclophosphamide pulses treatment for the induction therapy of LN(III,IV,V).
- Conditions
- Kidney Diseases, Lupus Nephritis, Tacrolimus, Induction Phase
- Trial name
- NCT00615173
- Testing
- tacrolimus (FK506), cyclophosphamide or azathioprine
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Sun Yat-sen University
Lupus Nephritis
ACTHar in the Treatment of Lupus Nephritis
Systemic Lupus Erythematosus (SLE) is a disease in which the immune system attacks the healthy cells and tissues, causing inflammation that can damage organs in the body.
- Trial name
- ACTHar (NCT02226341)
- Testing
- CellCept, ACTHar gel
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Systemic Lupus Erythematosus (SLE)
Efficacy of Vitamin C Supplementation on Serum IL-6 Levels and Disease Activity in Systemic Lupus Erythematosus Patients
The study aimed to evaluate the efficacy of vitamin C supplementation compared to placebo towards IL-6 levels and disease activity with the MEX-SLEDAI score in Systemic Lupus Erythematosus (SLE) patients.
- Trial name
- NCT07071220
- Testing
- Vitamin C
- Where
- Indonesia
- Volunteers
- 38 people
- Sponsor
- Universitas Sriwijaya
Systemic Lupus Erythematosus
Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations
Azathioprine is still considered the treatment of choice for the non-renal manifestations of systemic lupus erythematosus (SLE) with an estimated efficacy of 45%.Recently, several studies have demonstrated the efficacy of…
- Trial name
- NCT01112215
- Testing
- Azathioprine, Enteric-Coated Mycophenolate Sodium
- Where
- Spain
- Volunteers
- 240 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Systemic Lupus Erythematosus
CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE)
The key of this prospective study is to identify a potentially increased cardiovascular risk in patients with systemic Lupus erythematodes, with and without renal affection. Three groups of patients will be compared.
- Trial name
- CASTLE (NCT01520155)
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Systemic Lupus Erythematosus
Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)
The purpose of this study is to assess the PK, PD, and safety of anifrolumab as SC administration or IV infusion in adult participants with systemic lupus erythematosus (SLE).
- Trial name
- NCT07688980
- Testing
- Anifrolumab: SC formulation via AI, Anifrolumab: IV formulation, Anifrolumab: SC formulation via aPFS
- Volunteers
- 92 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Immun4Cure Cohort of Autoimmune Diseases
This prospective cohort study aims to constitute a 500-participant database and biobank including 450 adults with systemic autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis) and 50…
- Conditions
- Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Healthy Adult Volunteers
- Trial name
- Immun4Cure (NCT07515638)
- Testing
- Blood test and principal collection, Optional collection, Patient questionnaires
- Where
- France
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Systemic Lupus Erythematosus (SLE)
A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Doses of TJ202 in Patients with Systemic Lupus…
- Trial name
- NCT05140824
- Testing
- TJ202 injection
- Where
- 2 sites in China
- Volunteers
- 1 people
- Sponsor
- TJ Biopharma Co., Ltd.
Lupus Nephritis
A Study of Telitacicept in Lupus Nephritis
The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with active lupus nephritis.
- Trial name
- NCT05680480
- Testing
- Telitacicept 240 mg, Telitacicept 160 mg
- Where
- 45 sites in China
- Volunteers
- 120 people
- Sponsor
- RemeGen Co., Ltd.
Systemic Lupus Erythematosus
Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
The primary objective of this phase Ia study is to evaluate the safety and tolerability of single-ascending, subcutaneous (SC) doses of HC022 in healthy subjects.
- Trial name
- NCT06657703
- Testing
- HC022
- Where
- 3 sites in China
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- HC Biopharma Inc.
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants
The primary objective of this study is to perform mass balance following a single oral dose of [14C]CCX168 in healthy adult male participants.
- Trial name
- NCT06004960
- Testing
- [14C]CCX168
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Amgen
Systemic Lupus Erythematosus
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Moderate to Severe Active Systemic Lupus Erythematosus
- Trial name
- NCT06711146
- Testing
- Metabolically Armed CD19 CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhejiang University
Systemic Lupus Erythematosus
The Role of Some Hematological Parameters in Juvenile Systemic Lupue Erythematosus
Juvenile systemic lupus erythematosus is an autoimmune disorder with multisystem involvement, leading to inflammatory damage to the joints, kidney, central nervous system, and hematopoietic system.
- Trial name
- NCT06227559
- Volunteers
- 60 people
- Sponsor
- Assiut University
Lupus Erythematosus, Systemic, Lupus Nephritis
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
The purpose of this study is to examine the safety of a single dose of RG2077 in patients with systemic lupus erythematosus (SLE) who are currently receiving cyclophosphamide.
- Trial name
- NCT00094380
- Testing
- CTLA4-IgG4m (RG2077), Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Study of M5049 in CLE and SLE Participants
This study is to evaluate the safety, tolerability and pharmacokinetics (PK) of orally administered M5049 in participants with systemic lupus erythematosus (SLE) or cutaneous lupus erythematosus (CLE).
- Trial name
- NCT04647708
- Testing
- M5049
- Where
- 12 sites in Bulgaria, Germany and 4 more
- Volunteers
- 25 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.